Skip to main content

Table 6 Expression of selected urinary proteins between PH1 patients without and with nephrocalcinosis (NC) or kidney stones (KS)

From: Specific populations of urinary extracellular vesicles and proteins differentiate type 1 primary hyperoxaluria patients without and with nephrocalcinosis or kidney stones

Measured urinary proteins by antibody array Primary hyperoxaluria type 1 (PH1) Statistical Results
PH1 without NC or KS (n = 6) PH1 patients with NC (n = 6) PH1 patients with KS (n = 6) p value Q value
Complement C5a 1.0 (0.9, 1.9) 1.0 (0.7, 1.4) 2.0 (1.2, 2.7) 0.08 0.23
CD14 12.8 (6.1, 15.9) 4.5 (3.7, 5.6) 7.1 (5.1, 9.6) 0.02 0.12*
CD40 2.3 (1.6, 4.1) 1.6 (1.3, 2.0) 3.4 (2.1, 4.5) 0.00 0.12*
Coagulation factor III 0.8 (0.4, 2.0) 0.6 (0.4, 1.0) 1.1 (0.5, 1.9) 0.42 0.56
Coagulation factor VII 2.8 (2.5, 4.3) 1.9 (1.6, 3.1) 3.6 (2.5, 5.0) 0.06 0.19*
Coagulation factor XIV 2.3 (1.5, 3.8) 1.6 (1.5, 2.7) 3.0 (1.8, 4.3) 0.28 0.43
C-reactive protein 18.9 (15.0, 24.0) 13.9 (12.0, 15.5) 16.9 (14.4, 20.7) 0.01 0.12*
E-cadherin 3.7 (2.0, 5.8) 2.1 (1.8, 2.6) 3.7 (3.0, 4.6) 0.03 0.14*
EGFR 0.7 (0.4, 1.6) 0.5 (0.3, 1.0) 1.2 (0.9, 1.5) 0.04 0.16*
Endoglin 10.7 (9.1, 14.6) 9.8 (7.9, 9.9) 13.0 (11.8, 16.1) 0.02 0.12*
E-selectin 16.0 (14.9, 18.2) 13.8 (12.3, 16.9) 17.4 (16.1, 19.0) 0.27 0.42
Fetuin A 72.6 (45.7, 138.5) 31.8 (9.9, 56.4) 70.5 (40.5, 97.4) 0.02 0.12*
Glycoprotein VI 3.5 (1.9, 7.4) 3.0 (2.0, 3.6) 4.9 (2.6, 8.1) 0.42 0.56
ICAM-1 13.2 (8.4, 18.2) 9.9 (8.4, 13.1) 16.4 (11.9, 20.8) 0.09 0.25
Interleukin 10 0.7 (0.4, 1.1) 0.5 (0.3, 0.8) 0.8 (0.4, 1.3) 0.13 0.28
Insulin receptor 3.7 (3.2, 7.0) 3.5 (2.9, 3.8) 4.8 (2.6, 8.0) 0.26 0.42
LDLR 5.0 (4.3, 7.8) 4.2 (3.3, 4.4) 6.3 (3.2, 10.6) 0.16 0.30
MCP-1 27.0 (19.6, 32.9) 15.7 (11.8, 18.4) 23.9 (18.6, 30.6) 0.01 0.12*
MMP-2 4.0 (3.4, 9.9) 3.3 (2.8, 3.6) 4.7 (2.8, 7.1) 0.12 0.28
MMP-9 5.7 (4.3, 16.1) 3.8 (3.0, 5.2) 5.3 (2.9, 14.0) 0.38 0.54
Neprilysin 1.0 (0.8, 1.8) 0.7 (0.5, 0.9) 1.9 (1.1, 3.1) 0.02 0.12*
Osteopontin 50.8 (17.2, 80.1) 9.8 (7.5, 28.3) 46.5 (17.6, 74.5) 0.06 0.19*
Osteoprotegrin 9.5 (8.3, 12.8) 7.7 (6.5, 10.2) 11.0 (9.6, 15.4) 0.04 0.16*
PAI-1 0.8 (0.5, 1.1) 0.6 (0.3, 1.0) 0.9 (0.8, 1.0) 0.14 0.28
PDGFRβ 7.1 (5.3, 9.4) 5.3 (4.1, 6.6) 7.6 (5.8, 10.9) 0.06 0.19*
PDGF-AA 2.7 (1.3, 3.5) 2.2 (1.7, 2.9) 3.0 (1.4, 4.7) 0.71 0.77
PDGF-BB 6.1 (3.7, 8.7) 4.2 (3.1, 6.3) 8.2 (4.7, 11.9) 0.11 0.28
PECAM-1 4.5 (3.3, 6.2) 3.8 (3.2, 4.2) 4.4 (2.4, 6.2) 0.67 0.77
Pref-1 7.5 (3.6, 12.4) 5.4 (4.9, 8.2) 6.0 (3.0, 9.8) 0.71 0.77
P-selectin 16.6 (12.6, 19.6) 15.5 (13.6, 17.3) 15.9 (11.3, 21.3) 0.91 0.91
RANTES 13.5 (12.1, 24.8) 12.9 (11.8, 14.7) 15.1 (12.2, 18.6) 0.36 0.54
TFPI 1.3 (1.2, 2.9) 1.3 (1.2, 1.7) 2.1 (1.1, 3.1) 0.49 0.61
Thrombomodulin 1.8 (1.2, 2.9) 1.6 (1.2, 2.1) 2.4 (1.3, 3.2) 0.25 0.42
TIMP1 9.0 (4.7, 15.0) 4.7 (2.7, 7.2) 9.3 (3.8, 12.9) 0.14 0.28
TIMP2 4.9 (3.8, 9.7) 1.9 (1.1, 6.3) 3.7 (2.0, 9.1) 0.16 0.30
TLR4 1.2 (0.7, 1.8) 1.0 (0.6, 1.3) 1.2 (0.7, 1.5) 0.52 0.63
Troponin I 10.5 (7.5, 14.4) 10.5 (8.4, 11.2) 10.6 (5.4, 16.1) 0.91 0.91
VCAM-1 2.2 (1.3, 3.4) 2.2 (1.6, 2.8) 2.7 (1.7, 3.9) 0.45 0.58
VE-cadherin 0.8 (0.5, 1.4) 1.1 (0.7, 1.2) 0.9 (0.6, 1.6) 0.62 0.73
VEGFR1 7.4 (5.6, 10.4) 7.5 (5.2, 8.6) 7.6 (5.7, 11.1) 0.88 0.91
  1. Data are presented as medians (25th and 75th percentile) of relative intensity of selected urinary proteins average pixel value
  2. C5a, complement component 5a; CD14, cluster of differentiation 14; CD40, cluster of differentiation 40; E-cadherin, epithelial cadherin; EGFR, epidermal growth factor receptor; E-selectin, endothelial selectin; ICAM-1, intercellular adhesion molecule-1; LDLR, low density lipoprotein receptor; MCP-1, monocyte chemoattractant protein-1; MMP-2, matrix metalloproteinase-2; MMP-9, matrix metalloproteinase-9; PAI-1, plasminogen activator inhibitor-1; PDGFRβ, platelet-derived growth factor receptor beta; PDGF-AA, platelet-derived growth factor-AA; PDGF-BB, platelet-derived growth factor-BB; PECAM-1, platelet endothelial cell adhesion molecule-1; pref-1, preadipocyte factor-1; RANTES, regulated upon activation, normal T-cell expressed and secreted; TFPI, tissue factor pathway inhibitor; TIMP1, tissue inhibitor of matrix metalloproteinase 1; TIMP2, tissue inhibitor of matrix metalloproteinase 2; TLR4, toll like receptor 4; VCAM-1: vascular cell adhesion molecule-1; VE-cadherin, vascular endothelial cadherin; VEGFR1, vascular endothelial growth factor receptor 1
  3. *False discovery rate (FDR) Q-value < 0.20 among PH1 patients groups